Unigrains buys minority stake in Nutrisens

As part of the deal, the GP acquired its minority stake from existing owner Evolem, a French family-owned industrial holding firm, which will retain a controlling stake after the transaction.

Following the deal, the company aims to develop new products that will allow it to target new pathologies. Moreover, it is keen on opening a new distribution channel with pharmacies and expand internationally through the opening of four new subsidiaries by 2020 in Australia, Belgium, Germany and the UK.

Company
Established in 2011, Nutrisens specialises in health and medical nutrition. It develops dietary therapies that aim to address long-term conditions and pathologies such as malnutrition, dysphagia and specific intolerances.

In 2016, the company posted €60m in revenues, of which 15% was generated overseas, according to a statement. Headquartered in Lyon, the business currently employs 236 people.

People
Unigrains – Sébastien Haselint (investment director); Fabrice Queniat (investment officer); Julien Becquet (analyst).
Evolem – François Noir (deputy CEO); Sandrine Escaleira (acquisitions and strategy director); Clément Venard (strategy and market analyst).
Nutrisens Group – Georges Devesa (CEO).

Advisers
Equity – Agilys Avocats (legal); Grant Thornton (financial due diligence).
Vendor – DC Advisory (corporate finance); Alcya Conseil (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Consumer
• France
• France